← Russell 3000 cross-section

ZYME Zymeworks Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$2.1bn
Revenue TTM
$37m
Net income TTM
$-150m
Free cash flow
$-120m
Composite score
26.9
Sector rank
#1630

Valuation

P / E
EV / EBITDA
EV / sales
50.7
FCF yield
-5.85%
Earnings yield vs 10-yr
-12.00pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-404.0%
EBITDA margin
-405.8%
ROE
-186.6%
ROIC
Revenue growth
-69.8%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We also expect that royalty revenue from Ziihera sales will increase as potential regulatory approvals are obtained in global markets for GEA. Under our collaboration agreement with Jazz, we are eligible to receive tiered royalties of ten to high teens percentages on global (outside of Asia (other than Japan), Australia and New Zealand) annual net sales of Ziihera up to $2.0 billion and 20% on annual net sales above $2.0 billion. …Zymeworks Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →